StockGuide AI - assistant for market research

Tech Giants Face Rising Costs Amid AI Investment Surge, with Amazon and Alphabet Reporting Negative Cash Flow

07/31/2026, 06:37 AM economy review software ai Amazon Microsoft Alphabet Tesla Apple

The ongoing AI investment surge among major tech companies is leading to significant cash flow challenges, with spending projected to reach $765 billion this year. This trend raises concerns about the sustainability of their financial health amid rising memory costs and competitive pressures from emerging AI models.

Analysts expect upside for Amazon (AMZN) shares after strong earnings report, while Apple (AAPL) faces challenges with weak guidance

07/31/2026, 06:37 AM economy review Analysts: analysts software internet Amazon Exxon Mobil Microsoft Chevron Apple

Microsoft's stock surged 15%, adding nearly $450 billion to its market cap, while Amazon and Apple reported contrasting earnings, impacting investor sentiment significantly.

New York State Sues Prediction Market Platform Kalshi for Alleged Illegal Gambling Operations

07/31/2026, 06:37 AM business announcement

New York state has filed a lawsuit against prediction market platform Kalshi, alleging it operates an illegal gambling business by not being registered with the state's Gaming Commission. This legal action could have significant implications for Kalshi and the broader prediction market sector, particularly regarding regulatory compliance and operational viability in New York.

Federal Reserve Officials Advocate for Immediate Rate Hikes to Combat Inflation

07/31/2026, 05:37 AM business announcement finance

Federal Reserve officials are advocating for immediate interest rate hikes to combat persistent inflation, highlighting concerns that delaying action could lead to more severe economic consequences. Their dissent against the current steady rate reflects a growing urgency to address inflationary pressures.

Analysts divided on Apple’s (AAPL) earnings as company faces supply constraints and weaker guidance

07/31/2026, 05:37 AM investing review Analysts: analysts software Apple

Apple's fiscal third-quarter earnings report showed strong revenue but disappointing guidance, leading to a significant drop in its stock price as investors reacted to potential growth challenges ahead.

Stocks Making Significant Moves Premarket: Replimune, Chevron, Apple, Amazon, Moderna, and More

07/31/2026, 05:37 AM business review Replimune Group Amazon Exxon Mobil Novo Nordisk Coinbase Chevron Moderna Apple

Premarket trading saw significant movements in various stocks, notably Replimune Group, which surged over 130% following positive FDA news, while Amazon's shares jumped over 11% due to strong cloud revenue growth.

More Consumer Companies Opt to Remain Private Longer, Avoiding IPOs Amid Market Changes

07/31/2026, 05:37 AM business review consumer

The trend of consumer companies opting to remain private rather than pursue initial public offerings (IPOs) is growing, reflecting significant changes in market dynamics and investor behavior since the IPO boom of 2021. This shift may impact future market activity and the strategies of both private and public companies.

Analysts Recurrent report used electric vehicle (EV) prices appreciating despite high supply

07/31/2026, 05:37 AM business review Analysts: analysts auto

The recent rise in used electric vehicle (EV) prices, contrary to typical depreciation trends, presents both opportunities and challenges for consumers, particularly as demand remains strong despite an increase in supply.

Financial Advisors Recommend Diversifying Investments Beyond Trump Accounts for Children’s Financial Security

07/31/2026, 05:37 AM business review finance State Street Corporation

The introduction of Trump accounts for children allows families to contribute up to $5,000 annually for tax-deferred retirement savings, but financial advisors emphasize the importance of diversifying investments beyond these accounts to enhance long-term financial security.

Novo Nordisk (NVO) Shares Drop 10% Following Failed Heart Drug Trial Results

07/31/2026, 05:37 AM business stock_drop healthcare Novo Nordisk

Novo Nordisk's shares dropped significantly after the company announced that its late-stage trial for the heart drug ziltivekimab failed to show a meaningful reduction in major adverse cardiovascular events compared to a placebo, raising concerns about its pipeline and market execution.

Feed